Gotowe bibliografie tematyczne / Cisplatin / Książki

Książki na temat „Cisplatin”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Cisplatin.
Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 6 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych książek naukowych na temat „Cisplatin”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj książki z różnych dziedzin i twórz odpowiednie bibliografie.

1

Ozols, Robert F. High-dose Platinol (cisplatin for infection) in hypertonic saline. Syracuse, N.Y: Bristol-Myers Oncology Division, 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Chu, Wendy. Mechanism of cisplatin resistance inhuman malignant melanoma. Ottawa: National Library of Canada, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Yoshihiro, Kikuchi, red. Mechanism of cisplatin resistance and its circumvention. Commack, NY: Nova Science Publishers, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Merazga, Yamina. Aspects of the interaction between cisplatin and renal glutathione. Uxbridge: Brunel University, 1990.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

1946-, Lippert Bernhard, red. Cisplatin: Chemistry and biochemistry of a leading anticancer drug. Zürich: Verlag Helvetica Chimica Acta, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Morley, Christopher. Analogues of cisplatin from diamino carbohydrates and related compounds. Norwich: University of East Anglia, 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Evans, Dyfed Llyr. The induction of apoptosis by the anticancer agent cisplatin. Manchester: Universityof Manchester, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Laurell, Göran. Ototoxicity of the anticancer drug cisplatin: Clinical and experimental aspects. Stockholm, Sweden: Distributed by Almqvist & Wiksell Periodical Co., 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pembrolizumab (nicht kleinzelliges Lungenkarzinom: Nutzenbewertung gemäß § 35a SGB V. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, 2017.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Bryant, Eric Edward. Systems Genetics of DNA Damage Tolerance – Cisplatin, RAD5 & CRISPR-mediated Nonsense. [New York, N.Y.?]: [publisher not identified], 2019.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
11

Kuduk-Jaworska, Janina. Przeciwnowotworowo aktywne kompleksy platyny. Wrocław: Wydawn. Uniwersytetu Wrocławskiego, 1992.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
12

International, Congress on Neo-Adjuvant Chemotherapy (2nd 1987 Paris France). Paraplatine: Carboplatine: symposium satellite du deuxième congrès international sur la chimiothérapie néo-adjuvante Paris, 20 frévier 1988. Paris: Libbey Eurotext, 1988.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
13

M, Beard S., i Trent Institute for Health Services Research. Working Group on Acute Purchasing., red. The use of cisplatin and paclitaxel as a first line treatment in ovarian cancer. Sheffield: Trent Institute for Health Services Research, 1997.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
14

Kuzniar, Beata. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity. Ottawa: National Library of Canada, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
15

Weinrib, Laura M. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma. Ottawa: National Library of Canada, 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
16

Obasaju, Coleman Kehinde. Methotrexate and cisplatin pharmacokinetics when used as neoadjuvant treatment in patients with poor progress cervical cancer. Manchester: University of Manchester, 1995.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
17

Malinowski, Jerzy. Sztuka i nowa wspólnota: Zrzeszenie Artystów Bunt, 1917-1922. Wrocław: "Wiedza o Kulturze", 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
18

H, McBrien D. C., i Slater T. F, red. Biochemical mechanisms of platinum antitumour drugs: Based on the proceedings of a symposium held at Brunel University, 3-5th July 1985. Oxford: IRL, 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
19

H, McBrien D. C., i Slater T. F. 1931-, red. Biochemical mechanisms of platinum antitumour drugs: Based on the proceedings of a symposium held at Brunel University, July 3-5, 1985. Oxford: IRL, 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
20

Souzamotta, Nando. Cisplatino versus Mandinga! Montevideo: Zignone Comics, 2011.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
21

Cabrelli, Matias. Presencia masónica en la Cisplatina. [Montevideo]: América Una, 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
22

Cabrelli, Alfonso Fernández. Presencia masónica en la Cisplatina. [Montevideo]: América Una, 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
23

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (5th 1987 Padua, Italy). Platinum and other metal coordination compounds in cancer chemotherapy: Proceedings of the Fifth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Abano Padua, Italy, June 29-July 2, 1987. Boston: Nijhoff, 1988.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
24

R, Kelland Lloyd, i Farrell Nicholas 1948-, red. Platinum-based drugs in cancer therapy. Totowa, N.J: Humana Press, 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
25

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (7th 1995 Amsterdam, Netherlands). Platinum and other metal coordination compounds in cancer chemotherapy 2. New York: Plenum Press, 1996.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
26

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (6th 1991 San Diego, Calif.). Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press, 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
27

Barroso, Gustavo. A Guerra do Vidéo: 1825-1828 : contos e episódios da Campanha da Cisplatina. [Fortaleza, Brazil]: UFC, Casa de José de Alencar, Programa Editorial, 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
28

Canez, Anna Paula. Arquiteturas cisplatinas: Roman Fresnedo Siri e Eladio Dieste em Porto Alegre. Porto Alegre, RS: UniRitter, Centro Universitário Ritter dos Reis, Faculdade de Arquitetura e Urbanismo, 2004.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
29

Lippert, Bernhard, red. Cisplatin. Wiley, 1999. http://dx.doi.org/10.1002/9783906390420.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
30

Brock, Patrick. Cisplatin Toxicity in Infants and Children. Leuven University Press, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
31

Prestayko, Archie W. Cisplatin: Current Status and New Developments. Elsevier Science & Technology Books, 2013.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
32

Kojima, Toshiko, i Yoko Morita. Cisplatin: Pharmacology, Clinical Uses and Adverse Effects. Nova Science Publishers, Incorporated, 2012.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
33

Bongers, Jacob. Platinum(II) metallothioneins. 1989.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
34

Lippert, Bernhard. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Wiley-VCH, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
35

Lippert, Bernhard. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Wiley & Sons, Limited, John, 2006.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
36

Publications, ICON Health. Cisplatin - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
37

Clinical and Preclinical Pharmacokinetic and Dynamic Studies with Cisplatin, Topotecan and Docetaxel. ICG Printing, 1996.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
38

Ajithkumar, Thankamma, Ann Barrett, Helen Hatcher i Natalie Cook. Appendix. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235636.003.0022.

Pełny tekst źródła
Streszczenie:
Systemic therapy regimens 692Radiotherapy fractionation 695Glomerular filtration rate 701Anatomical diagrams 702• Cisplatin 80–100mg/m2 IV infusion Day 1• 5-FU 1g/m2 24-hour infusion Days 1–5• 3-week cycle• 75mg/m2 for 42 days starting on the first day of radiotherapy. Give 1 hour prior to radiotherapy and morning at weekend...
Style APA, Harvard, Vancouver, ISO itp.
39

Pinkett, Georgia L. Cisplatinum: An antineoplastic agent with an ototoxic effect. 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
40

McBrien, D. C. H. Biochemical Mechanisms of Platinum Antitumour Drugs. Oxford University Press, USA, 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
41

(Editor), Lloyd R. Kelland, i Nicholas P. Farrell (Editor), red. Platinum-Based Drugs in Cancer Therapy (Cancer Drug Discovery and Development). Humana Press, 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
42

(Editor), Donald Henderson, Richard J. Salvi (Editor), Antonio Quaranta (Editor) i et al (Editor), red. Ototoxicity: Basic Science and Clinical Applications (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
43

Calabrò, Fabio, i Cora N. Sternberg. Treatment of metastatic bladder cancer. Redaktor James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0079.

Pełny tekst źródła
Streszczenie:
Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led to clinical investigation of several therapeutic targets. To date, these agents have yet to demonstrate an improvement in overall survival. Urothelial cancer is extremely sensitive to checkpoint inhibition with both anti PD-1 and anti PDL1 antibodies. The future seems brighter with the advent of these new therapies.
Style APA, Harvard, Vancouver, ISO itp.
44

Ball, Steve, i Sajid Kalathil. Adrenocortical cancer. Redaktor James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0094.

Pełny tekst źródła
Streszczenie:
Adrenocortical cancer (ACC) is rare and associated with poor prognosis. The incidence is estimated at 0.7–2 cases per one million. Overall survival rate at five years for ACC is 37–47%. While the pathogenesis of ACC is incompletely understood, inherited predisposition syndromes are common in childhood ACC. Clinical presentation can be with symptoms and signs of hormone excess (functional tumours), mass effects, or as an incidental radiological finding. A multidisciplinary approach combining radiology, biochemistry, and tissue-based pathology is needed to establish a diagnosis to guide a surgical approach aimed at complete resection of the tumour where possible. At present, recommended first-line therapies for advanced disease are mitotane monotherapy or etopiside, doxorubicin, and cisplatin plus mitotane. Metronomic capecitabine and gemcitabine have been used as alternatives. Adjuvant radiotherapy to the tumour bed should be considered for patients considered to be at high risk of recurrence.
Style APA, Harvard, Vancouver, ISO itp.
45

Hoskin, Peter. Vulva and vagina. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199696567.003.0014.

Pełny tekst źródła
Streszczenie:
Chapter 9b discusses carcinoma of the vulva, which is primarily a surgical disease best treated by wide surgical resection, radical vulvectomy, and inguinal lymph node dissection based on presenting stage. Rarely, locally advanced primary disease may be presented for primary radiotherapy treatment. Postoperative radiotherapy is recommended for tumours invading >7 mm in a vertical direction. The first station regional lymph nodes in the inguinal region are best treated by radical surgical dissection, but fixed inoperable lymph nodes may benefit from primary radiotherapy which may be followed where appropriate by surgery if there is a residual mass. Postoperative radiotherapy should be considered for women having more than one node involved with metastatic tumour at surgery. This must be balanced against the increased risk of lymphoedema where both surgery and radiotherapy are delivered to the groins. Chemoradiation using cisplatin or 5-FU/mitomycin C-based schedules has been reported but no randomized comparison with radiotherapy alone has been undertaken; whilst high response rates are seen there is a considerable increase in acute toxicity.
Style APA, Harvard, Vancouver, ISO itp.
46

Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer, 1996.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
47

D, Ahlgren James, Rotman Marvin 1933- i Rosenthal C. Julian, red. Concomitant continuous infusion chemotherapy and radiation. Berlin: Springer-Verlag, 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
48

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff i Madhumita Bhattacharyya. Breast cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0014_update_001.

Pełny tekst źródła
Streszczenie:
Thoracic cancer examines the epidemiology, aetiology, and role of screening and prevention in the reduction of deaths from lung cancer, the majority caused by cigarette smoking. The pathology and genetics of lung cancer, with particular note of the driver mutations, are followed by the symptoms and signs of the disease. Appropriate investigations are described to stage the tumour. The optimum treatment for localised non-small cell lung cancer (NSCLC) is surgical resection, followed in some cases by adjuvant chemotherapy. However, most cases present with disease too advanced for surgery, and for these chemotherapy and radiotherapy are appropriate. Metastatic NSCLC can be treated with platinum based doublet chemotherapy with modest palliative benefits. Metastatic NSCLC with specific driver mutations are amenable to control by targeted therapy. Locally advanced NSCLC is often treated with similar chemotherapy and radiotherapy, ideally administered concurrently, to achieve symptom relief but also improved survival rates. Short course simple radiotherapy offers symptom relief in patients not fit for chemotherapy. Patients with localised NSCLC who are not fit for surgery, may benefit from radical radiotherapy, particularly stereotactic radiotherapy. Small cell lung cancer (SCLC) is characterised by almost universal systemic spread, so that surgery is rarely appropriate. Staging is similar to NSCLC, and chemotherapy is the mainstay of treatment, usually cisplatin or carboplatin combined with etoposide. When possible, this is combined with concurrent thoracic irradiation covering all radiological sites of disease. Prophylactic cranial irradiation reduces the risk of CNS disease. Malignant pleural mesothelioma is caused by occupational asbestos exposure. Symptoms and signs, investigation and staging, and management are discussed. Thymic tumours, their pathology, presenting symptoms including paraneoplastic syndromes, investigation, staging and treatment are reviewed.
Style APA, Harvard, Vancouver, ISO itp.
49

Brady, L. W., C. Julian Rosenthal, Marvin Rotman i H. P. Heilmann. Concomitant Continuous Infusion Chemotherapy and Radiation. Springer London, Limited, 2012.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
50

Brady, L. W., C. Julian Rosenthal, Marvin Rotman i H. P. Heilmann. Concomitant Continuous Infusion Chemotherapy and Radiation. Springer London, Limited, 2012.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany bibliografiami na temat „Cisplatin” dla innych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii